NCT04462328 - Acalabrutinib and Durvalumab in Primary and Secondary Central Nervous System Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 29, 2021

Primary Completion Date

January 31, 2026

Study Completion Date

October 31, 2027

Conditions

Primary Central Nervous System Lymphoma

Interventions

DRUG

Durvalumab

Durvalumab will be administered over 60 minutes

DRUG

Acalabrutinib

Patients will take acalabrutinib orally every 12 hours (+/- 3 hours) daily.

Trial Locations (2)

The Ohio State University Hospital, Columbus

Washington University School of Medicine, St Louis